Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

Janssen image

Patient access schemes ‘lack transparency’

December 12, 2014
Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme

Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …

News
Janssen image

NICE U-turn over Janssen arthritis drug

December 9, 2014
Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab

NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …

News
Astrazeneca image

AstraZeneca buys biotech Definiens

November 4, 2014
Research and Development, Sales and Marketing AstraZeneca, Janssen, MedImmune, Pharmacyclics, binnig, definiens

AstraZeneca has strengthened its oncology capabilities with the acquisition of Definiens, a German company that has pioneered cancer imaging and …

News
The study will be conducted by Janssen image

BMS, Pharmacyclics and Janssen collaborate on cancer

October 14, 2014
Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo

Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …

News

Bexsero and Sirturo clear winners at UK Prix Galien Awards

October 2, 2014
Medical Communications, Research and Development, Sales and Marketing 2014, Bexsero, Janssen, Novartis, awards, prix galien, sirturo

The first TB medication to be approved in four decades and the first ever vaccine to treat invasive meningococcal disease …

News
J&J image

J&J bets $1.75 billion on virology

October 1, 2014
Research and Development, Sales and Marketing AL-8176, Alios BioPharma, J&J, JJ, Janssen, sovaldi, viral

Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral …

News
Jane Griffiths, company group chairman for Janssen EMEA and chairwoman of the EF

Janssen: why transparency is essential to the health of our industry

August 29, 2014
Medical Communications, Research and Development, Sales and Marketing EFPIA, EMEA, Goldacre, Janssen, alltrials, transparency

The pharmaceutical industry is moving forward, working together to ensure patients have access to new and innovative medicines.However, more must …

News
Zytiga image

Charities ‘disappointed’ in NICE and Janssen

August 15, 2014
Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, prostate

The Institute of Cancer Research and Prostate Cancer UK are both urging NICE and Janssen to ‘get their act together’ …

News
Roche

Roche’s blood cancer drug gains EU approval

July 29, 2014
Research and Development, Sales and Marketing CLL, Cancer, Gilead, Janssen, Roche

The European Commission has approved Roche’s new leukaemia drug Gazyvaro (obinutuzumab) as competition for the blood cancer market heats up. …

News
EMA HQ

EMA approvals for rival blood cancer drugs

July 27, 2014
Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig

Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …

News
Janssen image

NICE recommends tenth diabetes drug

June 26, 2014
Sales and Marketing Janssen, NHS, diabetes, invokana, type 2

In final guidance NICE has recommended Janssen’s Invokana as a treatment to help lower blood sugar levels in people with …

News
janssen image

Janssen abandons Simponi application

May 23, 2014
Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis

Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …

News
Janssen logo

Europe approves Janssen’s hep C drug Olysio

May 20, 2014
Research and Development, Sales and Marketing Janssen, hepatitis C, sovaldi

Janssen-Cilag International’s Olysio has been given marketing authorisation in the European Union for the treatment of adults with hepatitis C …

News
Zytiga image

NICE: no early Zytiga use

May 14, 2014
Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, johnson, prostate

Janssen has criticised NICE’s decision not to recommend Zytiga on the NHS at an earlier stage in the prostate cancer …

News
Stelara image

Stelara hit by final NICE rejection

March 28, 2014
Sales and Marketing Janssen, NICE, UK, arthritis, psoriatic, stelar

In final draft guidance released today NICE says it cannot recommend Janssen’s psoriatic arthritis drug Stelara. Specifically, the pricing watchdog …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025